No news!!!!, page-11

I agree. The company needs to make an announcement after posting this on the ASX in Dec last year:

The Directors are pleased to advise that Biotron Limited (‘Biotron’ or ‘the Company’) will be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (‘CROI’), to be held in Boston MA, USA in March 2020.

CROI is the preeminent international HIV-1 conference and brings together top basic, translational and clinical researchers from around the world to share the latest studies and developments in the ongoing battle against HIV/AIDS and related infectious diseases.

Since completing the BIT225-009 Phase 2 HIV-1 clinical trial and releasing positive results in late 2018, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225. This has involved detailed post-trial analyses of trial samples. These analyses now provide key information on how BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI.